打开APP

Circassia努力寻求拯救豚草过敏药物项目

  1. Circassia
  2. 豚草
  3. 过敏

来源:生物谷 2014-12-09 14:46

庞大的过敏人群讲过敏市场催生为一个极具潜力的市场。

2014年12月8日讯 /生物谷BIOON/ --随着现代工业的发展,过敏现象变得越来越普遍。所谓过敏是指有机体对某些药物或外界刺激的感受性不正常地增高的现象,药物过敏。过敏简单地说就是对某种物质过度敏感。当你吃下、摸到或吸入某种物质的时候,身体会产生过度的反应;导致这种反应的物质就是所谓的"过敏原"。

在正常的情况下,身体会制造抗体用来保护身体不受疾病的侵害;但过敏者的身体却会将正常无害的物质误认为是有害的东西,产生抗体,这种物质就成为一种"过敏原"。我们身边似乎充斥着不同的过敏原。有人对花粉过敏,有人对紫外线过敏,还有人对海鲜过敏等等。庞大的过敏人群讲过敏市场催生为一个极具潜力的市场。

而Circassia公司就是其中的佼佼者。不过,公司最近开发的用于治疗豚草过敏药物Ragweed-SPIRE临床二期研究缺遭遇了不小的挫折。在这项临床二期研究中,受试的280名患者未能对这一药物作出反应,Ragweed-SPIRE治疗组的患者的鼻腔症状和非鼻腔症状均未能有明显改善。这也是公司今年在伦敦证券交易所融资三亿三千万美元以来所遭受的最大的研究挫折。公司的研发部门目前正在进一步分析数据,试图在这次结果中找到一些有利线索。而目前的结果显示,Ragweed-SPIRE的最高剂量组疗效最为突出。因此,下一步公司将有可能寻求提高Ragweed-SPIRE的药物使用剂量。

这一结果似乎并未降低投资者对Circassia公司的信心,Circassia公司目前还有治疗螨虫过敏、灰尘过敏等过敏药处于中期和后期临床研究。(生物谷Bioon.com)

详细英文报道:

Circassia Pharmaceuticals' pipeline has suffered its first notable post-IPO setback. The British biotech's ragweed allergy drug failed to live up to expectations in a Phase IIb trial, prompting the company to dig deeper into the data in search of a path forward for the candidate.

First, the bad news. The drug, Ragweed-SPIRE, failed to generate statistically significant improvements in nasal and non-nasal symptoms across the 280 people with ragweed allergy who were enrolled in the study. Circassia's stock dipped 6% following the news, which is the first setback for the company's pipeline since it pulled off a record-busting $332 million IPO on the London Stock Exchange earlier this year. Circassia is now working to salvage something from the trial.

The company talked up a few promising avenues for further investigation when it broke the news to investors. All of the doses showed signs of efficacy, but the effect was most pronounced in the 70 patients who received the biggest blast of the drug. Circassia has previously trialled Ragweed-SPIRE at a higher dose and is considering returning to these levels in pursuit of a stronger response. The firm is also trying to pick apart the role an unexpectedly strong placebo response had on the outcome.

Circassia's ability to find an effective dose and clinical trial design for Ragweed-SPIRE is critical to the future of the drug, but is less important to the company as a whole. Peel Hunt analyst Paul Cuddon said Ragweed-SPIRE is a long shot compared to other drugs in Circassia's pipeline, Reuters reports, and accounts for just 6% of its risk-adjusted value. More is resting on the company's treatments for cat, house dust mite and grass allergies, all of which are in mid- to late-phase trials.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->